Literature DB >> 28093982

PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research.

Agnieszka Jankowska1, Artur Swierczek2, Grazyna Chlon-Rzepa1, Maciej Pawlowski1, Elzbieta Wyska2.   

Abstract

Phosphodiesterase 7 (PDE7) is an intracellular enzyme that specifically hydrolyzes the second messenger, cyclic-3',5'-adenosine monophosphate (cAMP), into inactive noncyclic nucleotide, 5'-AMP. To date, many structurally diverse compounds with PDE7 inhibitory properties have been described, including selective PDE7 inhibitors, dual PDE4/PDE7, PDE7/PDE8, and PDE7/GSK-3 inhibitors, and non-selective PDE inhibitors with high affinity for PDE7. Inhibitors of PDE7 have provided beneficial effects in animal models of inflammatory and neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and many others. This review is a comprehensive summary of the current state-of-the-art in the field of design and synthesis of PDE7 inhibitors, their physicochemical properties, biological evaluation, and structure-activity relationships as well as it highlights the updated evidence for a potential therapeutic utility of these compounds. Moreover, new approaches to obtain more effective and safer PDE7 inhibitors than those available now are presented. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  PDE7 inhibitors; SAR exploration; allosteric modulators; dual inhibitors; immunological diseases; inflammation; neurologicalzzm321990diseases

Mesh:

Substances:

Year:  2017        PMID: 28093982     DOI: 10.2174/0929867324666170116125159

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

Review 1.  Therapeutic Targeting of PDEs and PI3K in Heart Failure with Preserved Ejection Fraction (HFpEF).

Authors:  Valentina Sala; Jean Piero Margaria; Alessandra Murabito; Fulvio Morello; Alessandra Ghigo; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2017-06

2.  Evaluation of analgesic and anti-inflammatory activity of purine-2,6-dione-based TRPA1 antagonists with PDE4/7 inhibitory activity.

Authors:  Małgorzata Zygmunt; Marietta Ślusarczyk; Agnieszka Jankowska; Artur Świerczek; Adrian Bryła; Szczepan Mogilski; Grzegorz Kazek; Jacek Sapa; Elżbieta Wyska; Grażyna Chłoń-Rzepa
Journal:  Pharmacol Rep       Date:  2022-08-05       Impact factor: 3.919

3.  Pharmacokinetic/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis.

Authors:  Artur Świerczek; Bartosz Pomierny; Elżbieta Wyska; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2022-02-27       Impact factor: 4.402

Review 4.  Pharmacological modulation of phosphodiesterase-7 as a novel strategy for neurodegenerative disorders.

Authors:  Heena Khan; Chanchal Tiwari; Amarjot Kaur Grewal; Thakur Gurjeet Singh; Simran Chauhan; Gaber El-Saber Batiha
Journal:  Inflammopharmacology       Date:  2022-10-22       Impact factor: 5.093

Review 5.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

6.  PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.

Authors:  Artur Świerczek; Hanna Plutecka; Marietta Ślusarczyk; Grażyna Chłoń-Rzepa; Elżbieta Wyska
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

7.  PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.

Authors:  Artur Świerczek; Elżbieta Wyska; Sebastian Baś; Marta Woyciechowska; Jacek Mlynarski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-07-20       Impact factor: 3.000

Review 8.  New Avenues for Phosphodiesterase Inhibitors in Asthma.

Authors:  Maria Gabriella Matera; Josuel Ora; Francesco Cavalli; Paola Rogliani; Mario Cazzola
Journal:  J Exp Pharmacol       Date:  2021-03-15

9.  Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach.

Authors:  Artur Świerczek; Krzysztof Pociecha; Marietta Ślusarczyk; Grażyna Chłoń-Rzepa; Sebastian Baś; Jacek Mlynarski; Krzysztof Więckowski; Monika Zadrożna; Barbara Nowak; Elżbieta Wyska
Journal:  Pharm Res       Date:  2020-01-02       Impact factor: 4.200

Review 10.  Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions.

Authors:  Marianna Szczypka
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.